Q1 2024: Kuros Reveals Corporate Highlights, Notably a Surge in Direct MagnetOs™ Sales

• Kuros Biosciences reported a 155% increase in direct MagnetOs sales in Q1 2024, reaching CHF 13.9 million, up from CHF 5.4 million in Q1 2023.
• Total sales for the Kuros Medical Devices segment also increased, reaching CHF 13.9 million in Q1 2024, up from CHF 5.6 million in Q1 2023.
• The Kuros Medical Devices segment achieved a positive EBITDA of CHF 3.9 million in Q1 2024, compared to CHF 0.5 million in Q1 2023.
• The company's cash and cash equivalents amounted to CHF 13.7 million, with total funds available (including trade and other receivables) totaling CHF 23.5 million as of March 31, 2024.
• MagnetOs Putty, the fourth product in the MagnetOs portfolio, received FDA 510(k) clearance for interbody use.
• A recent independent clinical study using MagnetOs Putty in lumbar interbody fusion procedures showed an 86% fusion rate, including 49% of study subjects in a high-risk patient cohort.

The next important date, Quarterly report, at Kuros Biosciences is on 24.04.2024.

Kuros Biosciences

+0,15 %

-2,78 %

+10,11 %

+22,04 %

+369,66 %

+282,58 %

+248,07 %

-69,30 %

ISIN:CH0325814116WKN:A2ALS5

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max